Jeffrey has made over 3 trades of the Progyny Inc stock since 2017, according to the Form 4 filled with the SEC. Most recently he sold 1,695 units of PGNY stock worth $42,816 on 11 June 2018.
The largest trade he's ever made was selling 13,875 units of Progyny Inc stock on 23 May 2018 worth over $335,775. On average, Jeffrey trades about 1,326 units every 14 days since 2017. As of 11 June 2018 he still owns at least 43,407 units of Progyny Inc stock.
You can see the complete history of Mr. Park stock trades at the bottom of the page.
Jeffrey Gary Park serves as Independent Director of the Company. Mr. Park has served since April 2019 as the Chairman and Chief Executive Officer of WellDyneRx, an independent pharmacy benefits manager. From January 2018 until May 2018, he was the Interim Chief Executive Officer of Diplomat Pharmacy, Inc., or Diplomat, a provider of specialty pharmacy services. Additionally, from June 2017 to February 2019, he served on the board of directors of Diplomat. Prior to that, from July 2015 until July 2016, he was the Chief Operating Officer of OptumRX, the entity resulting from the merger of Catamaran Corporation, or Catamaran, and OptumRX, UnitedHealthcare Group’s free-standing pharmacy care services business. Before the merger, from March 2014 until July 2015, he was Catamaran’s Executive Vice President, Operations, and previously served as Catamaran’s Chief Financial Officer, beginning in 2006. Mr. Park holds a Bachelor of Science degree in Accounting from Brock University.
As the Independent Director of Progyny Inc, the total compensation of Jeffrey Park at Progyny Inc is $330,651. There are 6 executives at Progyny Inc getting paid more, with David Schlanger having the highest compensation of $4,964,200.
Jeffrey Park is 48, he's been the Independent Director of Progyny Inc since 2019. There are 12 older and 3 younger executives at Progyny Inc. The oldest executive at Progyny Inc is Norman Payson, 72, who is the Independent Director.
Jeffrey's mailing address filed with the SEC is C/O PROGYNY, INC., 1359 BROADWAY, 2ND FLOOR, NEW YORK, NY, 10018.
Over the last 5 years, insiders at Progyny Inc have traded over $949,717,514 worth of Progyny Inc stock and bought 76,923 units worth $999,999 . The most active insiders traders include Group Holdings (Sbs) Adviso..., Plc Gsk e Gp A, Llcbonderman Davidcou.... On average, Progyny Inc executives and independent directors trade stock every 4 days with the average trade being worth of $2,005,422. The most recent stock trade was executed by Michael E Sturmer on 16 July 2024, trading 9,030 units of PGNY stock currently worth $270,900.
progyny is the leading fertility benefits company that combines service, science, technology and data to provide fertility solutions for self-insured employers. progyny’s approach offers members a comprehensive value based treatment plan that is based on the latest medical science and technology. the benefit plans are designed to improve outcomes, shorten time to pregnancy and reduce total fertility-related costs. progyny supports all fertility solutions to include ivf, iui, embryo banking, egg freezing, adoption and surrogacy.
Progyny Inc executives and other stock owners filed with the SEC include: